ThromboGenics NV - Q3 2009 Busin...(dema (DME). - Results from the Ph...)

- Results from the Phase IIa trial presented at the American

Society of Retina Specialists (ASRS) Conference in New York

In October 2009, ThromboGenics announced results from the Phase II trial of microplasmin intravitreal injection for treatment of DME (MIVI II DME). The trial showed that microplasmin was safe and well tolerated and that microplasmin is able to non-surgically resolve vitreomacular adhesion in some DME patients. The data from this trial were presented at the ASRS Conference in New York on 3 October, 2009 by Professor Peter Stalmans, University Hospitals Leuven, Belgium.

The MIVI II DME trial was designed to be the initial step in evaluating microplasmin in patients with diabetes, a group which is more prone to eye disease, and specifically diabetic retinopathy. ThromboGenics will finalize the next step in the development plan for microplasmin in this patient population once the results from the first Phase III trial (TG-MV-006) are reported. These results will provide significant additional data that will help ThromboGenics to refine the development plans for microplasmin in patients with diabetic retinopathy.

TB-402 - Phase II trial assessing the long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopedic surgery.

    - Phase II trial has completed recruitment of 315 patients
      ahead of schedule
    - Results are expected in the second quarter of 2010

In October, ThromboGenics announced the completion of patient recruitment for the Phase II trial of TB-402 ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopedic surgery. It is anticipated that the results of this study, which has recruited 315 patients, will be presented in the second quarter of 2010.

TB-402 has
'/>"/>